Pemetinib/pemetinib latest drug price in 2025

Pemigatinib (Pemigatinib) is an oral small molecule targeted drug that has attracted great attention in recent years. It mainly targets a special molecular pathway abnormality. As an FGFR (fibroblast growth factor receptor) inhibitor, pemetinib blocks the signaling of cancer cells and interferes with their growth and division processes, thereby inhibiting tumor progression.

The drug was initially approved in the European and American markets and is mainly used to treat patients carrying specificFGFR gene mutations. Especially when conventional treatment options are limited, it provides new hope for patients. Globally, with the development of medicine, pemetinib has gradually been included in more treatment pathways and has attracted the attention of clinicians. It is currently mainly used for the treatment of cholangiocarcinoma (CCA).

In terms of price, pemetinib has been launched in China, but its price is still relatively high. Currently, the common specifications on the market are 4.5 mg 14 tablets and 9 mg 14 tablets. The prices of different specifications vary greatly, with the overall range ranging from RMB 20,000 to RMB 50,000 per box. Since it is not yet covered by medical insurance, the financial burden on patients is still heavy. In overseas markets, the price is higher. For example, for the specifications of 13.5 mg and 14 tablets, the price per box may be as high as more than 70,000 yuan, and the price will fluctuate due to exchange rate changes.

It is worth noting that imitation versions have appeared in some countries and regions, such as the 4.5mg 14-piece product produced in Laos, which only costs more than 700 yuan per box. These generic drugs are highly consistent in ingredients with original drugs and have obvious price advantages, but drug purchase channels and quality assurance also need to be carefully screened.

Overall, the application value of pemetinib is closely related to the price trend. It not only provides patients with precise treatment options, but also poses new challenges to medical accessibility.

Reference materials:https://go.drugbank.com/drugs/DB15102